About ISLA Pharmaceuticals

Isla Pharmaceuticals is a Puerto Rico-based company with a rapid and efficient development strategy for tropical disease therapies.

We have obtained exclusive rights for our lead product candidate and are advancing quickly towards initiation of clinical trials.

News Release

  • Oct. 20, 2020
  • Isla Pharmaceuticals, a US-based company focused on rational repurposing of molecules for the treatment or prevention of viruses is pleased to announce that a key patent relating to the Company’s lead program, Isla101 has been granted by the Brazilian Industrial Property Office.
    Click to see full news release


    • Developing ISLA101 for the treatment of Dengue infection and other mosquito borne illnesses
    • Exclusive license for an international IP portfolio for the program
    • Lead compound has been in approximately 40 clinical trials for other indications with excellent safety profile
    • More than 10,000 patients treated with the lead compound but it is not yet approved
    • Repurposing strategy allows for rapid and less expensive path to approval
    • Shortened path to potential exit or revenue
    • If first approval for lead candidate, eligible for Tropical Disease Priority Review Voucher (PRV).
    • Recent PRVs have sold in excess of $120MM.
    • Desarrollando ISLA101 para el tratamiento del dengue y otras enfermedades transmitidas por mosquitos
    • Licencia exclusiva para una cartera internacional (CI) para el programa
    • El compuesto principal se ha utilizado en al menos 40 pruebas clínicas para otras indicaciones con excelentes resultados de seguridad
    • Sobre 10,000 pacientes han sido tratados con el compuesto principal, pero no ha sido aprobado para algo
    • La estrategia de Reasignación permite una vía rápida y menos costosa para ser aprobada
    • El camino hacia una ganancia o salida viable ha sido reducido
    • Si la primera aprobación es para el candidato principal, seria elegible para un Vale de Revisión de Prioridad de Enfermedades Tropicales (VRP).
    • Los Vales de Revisión de Prioridad más recientes se han vendido en sobre $120MM

    Mosquito borne infection

    Up to 700 million people are infected and more than a million die each year from mosquito borne illness.

    While the majority of cases occur in endemic and subtropical regions, because of increased international travel and migration patterns, prevalence in North America is increasing. Recent outbreaks of Zika, Dengue, West Nile and Yellow Fever have resulted in significant harm to patients and billions of dollars in damage to effected economies.

    ISLA’s Team

    Isla Pharmaceuticals’ team is made of experienced innovators and investors in the life science industry. Please see our Team page for details on some of our valued team members.